EDUCATIONAL ADVERTORIAL · NUTRITION AND TRAINING SUPPORT DURING GLP-1 TREATMENT
Educational content · Not medical advice
FOR WOMEN USING GLP-1 MEDICATIONS UNDER MEDICAL CARE

The Medication Decides How Much You Lose. It Does Not Decide What You Lose.

In clinical research, roughly a third of the weight lost on GLP-1 medications was lean mass, not fat. Here are the three habits women are building so the weight they lose is the weight they actually want to lose.

SEE THE 3 MUSCLE-FIRST HABITS

Educational only. Medication decisions belong with a licensed healthcare provider.

BUILT ON RESEARCH PUBLISHED IN

New England Journal of Medicine · JAMA · Diabetes, Obesity and Metabolism

Peer-reviewed sources cited throughout. This product is not endorsed by these journals.

WEIGHT LOST ON GLP-1 TREATMENT Fat Lean mass roughly two thirds roughly one third

Illustrative, based on ranges discussed in published research.

START HERE

Three habits that decide what the scale is hiding

  1. 1

    Protect your protein floor.

    When appetite shrinks to a few bites per meal, protein is usually the first thing that quietly disappears. A protein floor means a planned minimum, decided in advance, eaten first on the plate.

  2. 2

    Give your muscle a reason to stay.

    In a calorie deficit, the body tends to keep what it uses. Two short strength sessions per week are the signal that says: keep the muscle, burn the fat.

  3. 3

    Track more than the scale.

    The scale cannot tell fat from muscle. Simple weekly measurements, strength benchmarks, and energy scores can.

The complete GLP-1 Companion Toolkit organizes these habits into one practical system.

SEE THE COMPLETE TOOLKIT

Feeling weaker or more tired is not a sign you are failing.


GLP-1 medications can quiet appetite so effectively that eating becomes an afterthought. When overall food intake drops fast, protein often drops with it, and rapid weight loss without enough protein and strength training can cost lean mass along with fat.

That is not a discipline problem. It is a fueling and training problem, and it is addressable.

The goal is not to eat less than the medication already makes you eat. The goal is to make what you do eat, and what you do in two short sessions a week, protect the part of you that keeps your metabolism, strength, and shape.

You are not imagining it. Listen to the communities.

Down 28 pounds and I cannot open a jar I could open in January.

My doctor said eat more protein. On six bites of appetite? How exactly?

Paraphrased from recurring themes in public GLP-1 communities. These are not customers of this product and do not endorse it.

WHAT RESEARCH SUGGESTS

Weight loss and fat loss are not the same thing.

In a body composition sub-study of the STEP 1 trial, participants losing weight on semaglutide lost a meaningful share of that weight as lean mass rather than fat. Published analyses discuss figures in the range of roughly one third of total weight lost.

Researchers also observed what happens after treatment ends: in extension studies, a large portion of lost weight was regained by many participants within a year of stopping. The habits and muscle you build during treatment are what remain afterward.

THE LEAN LOSS GAP

Researchers call the pattern simple biology. We call it the Lean Loss Gap: the medication creates the deficit AND removes the appetite that used to deliver your protein. Nothing in the prescription itself protects the muscle. That part is yours to close, and it is very closeable.

Muscle affects more than looks.

Lean mass supports strength, joints, energy, and resting metabolism.

Protein and strength training are the levers.

Both are repeatedly discussed in the clinical literature around GLP-1 treatment. The details should fit your body and your clinician's guidance.

Clinical support still matters.

Medication decisions and concerning symptoms belong with a licensed healthcare provider.

View research references

What makes treatment results fragile


  1. 1

    Tracking only the scale.

    Short-term scale changes reflect water, sodium, digestion, and cycle. The scale also cannot tell you whether a lost pound was fat or muscle.

  2. 2

    Cutting food even further when loss slows.

    With an already tiny appetite, cutting more usually means losing the protein that muscle depends on.

  3. 3

    Choosing cardio over strength.

    Walking is valuable. But the signal to keep muscle in a deficit comes primarily from resistance training, not from more cardio.

VIEW THE COMPANION TOOLKIT

This toolkit may be useful if:


MEET THE TOOLKIT

Meet the GLP-1 Companion Toolkit


A complete digital system designed to help women protect muscle and energy during GLP-1 treatment: a 90-day companion guide, a muscle protection training plan, a protein-first meal system for small appetites, tracking tools that see more than the scale, and preparation for clearer conversations with your care team.

VIEW THE COMPLETE TOOLKIT

This educational toolkit does not advise you to start, stop, or change medication. Make medication decisions with your licensed healthcare provider.

References


  1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021;384:989-1002. doi:10.1056/NEJMoa2032183 (including body composition sub-study analyses)
  2. Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725
  3. Rubino DM, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial." JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
  4. Aronne LJ, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945

Research citations are provided for informational context only. They do not constitute endorsement of this product by the cited authors or institutions.

SEE THE TOOLKIT